Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by University of Zurich.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT01207843
First received: September 21, 2010
Last updated: September 22, 2010
Last verified: September 2010
  Purpose

Hepatic candidiasis is a frequent complication in patients receiving intensive chemotherapy for acute leukemia. Hepatic lesions may be detected by computerized tomographic (CT) scans, but there is no standardized CT protocol for the diagnosis and follow-up of hepatic candidiasis.

The investigators compared the size of the fungal lesions in the chest and abdomen CT. The current analysis aimed to increase the value of CT for the diagnosis and the follow-up of hepatic candidiasis in daily routine.


Condition Intervention Phase
Leukemia
Infection
Behavioral: Imaging
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Verbesserung Der Radiologischen Diagnose Von Hepatolienaler Candidiasis während Der Therapie Der Leukämie

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Estimated Enrollment: 60
Study Start Date: October 2009
Estimated Study Completion Date: November 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Imaging
    CT image validation and lesion measurement, as well as comparison of different CT phases
  Eligibility

Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients with suspected hepatolienal candidiasis.

Criteria

Inclusion criteria:

  • Chest and Abdomen CT with fungal lesion in patients with leukemia

Exclusion criteria:

  • Other liver pathologies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01207843

Contacts
Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Locations
Switzerland
Recruiting
Zurich, Switzerland
Principal Investigator: Thomas Frauenfelder, MD         
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: Thomas Frauenfelder, M.D., University Hospital of Zurich
ClinicalTrials.gov Identifier: NCT01207843     History of Changes
Other Study ID Numbers: idr-3d-001
Study First Received: September 21, 2010
Last Updated: September 22, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Zurich:
Computed tomography

Additional relevant MeSH terms:
Candidiasis
Leukemia
Mycoses
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on July 31, 2014